Firstly, several insightful posts about the company have been made in the thread , including the video interview and have helped me. Thankyou!
I was going through the AR today and it seems that the API production has been pushed by another quarter, now commencing from Q3 FY’24 instead of Q2 but the management says any temporary setbacks (caused by the delay) will be compensated by the capsules business which they are hoping to pickup in the coming quarters probably based on the sequential addition of HPMC capsules which may bring better margins.
While I was preparing myself for such a likelihood(for the short-term), wasn’t exactly expecting further delays as regards the API piece ,even though it is heartening to hear them consider Allocating 3.5-4% to R&D. It’d be very helpful if experts and the sector watchers could add their thoughts. Thankyou.
P.S – Invested and could be biased
| Subscribe To Our Free Newsletter |
